CHPA issues statement on FDA postponing April 12 NDAC meeting
WASHINGTON – The Consumer Healthcare Products Association (CHPA) released the below statement following the U.S. Food and Drug Administration’s (FDA) announcement that it will postpone its previously scheduled April 12 Nonprescription Drugs Advisory Committee (NDAC) meeting to reconsider the efficacy of oral phenylephrine (PE): “CHPA is pleased to see today’s news that FDA has postponed the
